BofA lowered the firm’s price target on Canopy Growth (CGC) to 80c from 98c and keeps an Underperform rating on the shares. On April 3, the White House laid out its Drug Policy priorities for the first year of President Trump’s term and cannabis rescheduling that was started under President Biden was not part of the list, the analyst noted. The firm cut its price target for Canopy given “continued unfavorable industry news and market conditions,” the analyst added.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGC:
- Lost Money on Canopy Growth Corporation(CGC)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky LLP
- Largest borrow rate increases among liquid names
- Canopy Growth Launches Spectrum Reserve: A New Premium Medical Cannabis Brand
- Canopy Growth Reduces Debt with Early Loan Prepayment
- Canopy Growth price target lowered to C$1.40 from C$1.70 at BofA
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue